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TO THE EDITOR
Primary cutaneous large B-cell lym-
phoma, leg type (PCLBCL-LT) is an
aggressive cutaneous lymphoma with a
5-year overall survival of approximately
40%. Because of its aggressive nature,
the treatment of first choice is anthracy-
clin-based chemotherapy combined
with rituximab (Senff et al., 2008). How-
ever, patients often show a progressive
disease course despite treatment with
polychemotherapy. Furthermore, owing
to age and comorbidity, not all patients
are eligible for this treatment. Therefore,
new and additional therapies for
PCLBCL-LT are necessary, with a focus
on more specific, targeted therapies
with fewer side effects than
conventional chemotherapy. At the
mRNA expression level, PCLBCL-LT
resembles nodal activated B-cell-type
diffuse large B-cell lymphoma (ABC-
DLBCL), including strong expression of
known targets of the NF-kB pathway,
such as IRF4 (Davis et al., 2001;
Hoefnagel et al., 2005). In nodal
ABC-DLBCL, increased NF-kB activity
has a role in its pathogenesis through
transcriptional activation of genes
involved in cellular survival mechani-
sms. Previous studies demonstrated that
mutations in multiple genes can cause
deregulation of NF-kB signaling in nodal
ABC-DLBCL (Compagno et al., 2009).
The genes most frequently affected
by these NF-kB-activating genetic
aberrations are TNFAIP3 (A20), CD79B,
CARD11 (CARMA1), and MYD88, which
we investigated in 10 cases of PCLBCL-
LT (Supplementary Table S1 online).
TNFAIP3 (A20) is a tumor suppressor
gene, downregulating NF-kB signaling
by targeting several proteins involved in
the activation of this pathway. By quan-
titative PCR, transcriptional levels of
TNFAIP3 varied in our PCLBCL-LT cases
(Supplementary Figure S1 online), and
therefore we investigated potential
underlying mechanisms for this variation.
Four cases with relatively low mRNA
expression levels showed heterozygous
deletion of the gene region by high-
density fine-tiling comparative genomic
hybridization. Homozygous deletions as
observed in 10% of nodal ABC-DLBCL
(Compagno et al., 2009) were not found.
In cases without deletion of TNFAIP3,
but displaying relatively low levels of
mRNA, we could not detect epigenetic
silencing through promoter hypermethy-
lation, as was encountered in approxi-
mately 40% of nodal ABC-DLBCL
(Honma et al., 2009). Possibly, in these
cases, reduced mRNA expression was
regulated by altered transcription factorAccepted article preview online 13 June 2013; published online 18 July 2013
Abbreviations: ABC-DLBCL, activated B-cell-type diffuse large B-cell lymphoma; cDNA, complementary
DNA; PCLBCL-LT, primary cutaneous large B-cell lymphoma, leg type
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activity. One-third of cases of nodal
ABC-DLBCL display genetic alterations
in intron 3, leading to transcripts with a
premature stop codon, giving rise to
truncated nonfunctional proteins. Again,
we could not detect these transcripts
in PCLBCL-LT. As TNFAIP3 was
demonstrated to influence proliferation
and survival in normal B cells in a gene
dose–dependent manner (Chu et al.,
2011), the relatively low expression of
TNFAIP3 in most of the PCLBCL-LT
samples can still be functionally rele-
vant and might suggest a role for this
tumor suppressor in the pathogenesis of
PCLBCL-LT.
CD79B is a component of the B-cell
receptor, and has a combined function
with CD79A in activating the NF-kB
pathway (Figure 1; Dal Porto et al.,
2004). Recurrent somatic mutations in
the first immunoreceptor tyrosine-based
activation motif tyrosine Y196 of
CD79B were detected in 18% of
nodal ABC-DLBCL. NF-kB pathway
activation through this mutation is
called chronic active B-cell receptor
signaling, and occurs in cases with wild-
type CARD11. In our series, concordant
with nodal ABC-DLBCL, in 20% an
Y196 mutation was detected in DNA
and complementary DNA (cDNA), in
the absence of mutations in CARD11,
suggesting that chronic active B-cell
receptor signaling is a mechanism
involved in these cases of PCLBCL-LT.
CARD11 is a signaling scaffold pro-
tein that functions as a critical compo-
nent in constitutive NF-kB activation in
ABC-DLBCL (Ngo et al., 2006), down-
stream of the B-cell receptor (Figure 1).
In one sample, we found a missense
mutation in codon 415 of exon 9
(D415E), and a R423W mutation in the
same exon in both DNA and cDNA.
The functional relevance of these D415E
and R423W mutations is not known.
However, mutations in the coiled-coil
domain of CARD11, as encountered in
10% of nodal ABC-DLBCL, are
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Figure 1. Pathway overview and genetic aberrancies in primary cutaneous large B-cell lymphoma,
leg type. The suggested relations between the different components of B-cell receptor signaling
and MYD88 signaling are represented (Yang et al., 2012). The molecules affected by genetic aberrancies
in PCLBCL-LT are indicated in red, and the percentages of cases affected by these aberrancies are
indicated. Molecules that can be therapeutically targeted for inhibition of the NF-kB pathway are
represented in green.
Table 1. Overview of genetic aberrancies
TNFAIP3/A20 CD79B CARD11 MYD88
Splicing site Y196 ITAM mutation Mutation coiled-coil domain L265P mutation
Case Del. Hypermethylation qPCR (DDCq) Mut. Splice variant DNA cDNA Exons 5–8 and 10 Exon 9 DNA cDNA
1 No No 0.50 No No No No No No L265P L265P
2 No No 0.51 No No No No No No No No
3 No No 0.08 No No No No No No No No
4 ± No 0.11 No No No No No No L265P L265P
5 ± No 0.13 No No No No No D415E, R423W No No
6 No No NA NA NA No No No No1 No No
7 No NA 0.03 No No Y196H Y196H No No L265P No
8 No No 0.17 No No Y196F Y196F No No L265P L265p
9 ± NA 0.01 No No NA No No No NA No
10 ± No 0.01 No No No No No No1 No No
Abbreviations: cDNA, complementary DNA; Del., deletion; Mut., mutation; NA, not assessed; qPCR, quantitative PCR; ±, heterozygous deletion.
1A silent mutation (D415D) was delected.
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potentially relevant in constitutive acti-
vation of the NF-kB pathway, as
changes in this domain have the poten-
tial to disrupt autoinhibition of CARD11
signaling, leading to receptor-indepen-
dent activation (Lamason et al., 2010).
MYD88 is a Toll-like receptor–asso-
ciated adaptor protein, among others
involved in the activation of NF-kB
signaling (Figure 1). Nodal ABC-DLBCL
showed L265P mutations in 29% of
cases, and the consequent amino-acid
substitution in the bD sheet of MYD88
has been shown to be oncogenically
active, leading to aberrant activation of
NF-kB signaling (Ngo et al., 2011), a
mechanism most likely not related to
(chronic active) B-cell receptor signaling
(Figure 1). Somatic MYD88 L265P muta-
tions in PCLBCL-LT have been previously
described in 69% of cases (Pham-Ledard
et al., 2012). We encountered a 40%
mutation rate in our series, concordant
with nodal ABC-DLBCLs. Furthermore,
we showed that not all mutations in the
DNA seem to be transcribed to mRNA,
as for one sample the mutation was not
detected in cDNA.
The relevance of the above-described
mutations for novel therapeutic strategies
has already been explored. For example,
sotrastaurin can interfere with NF-kB
signaling by the inhibition of PKC-b,
which is required for CARD11-dependent
activation of the NF-kB pathway (Sommer
et al., 2005). In a mouse model, sotra-
staurin was selectively toxic for CD79-
mutant DLBCL (Naylor et al., 2011)
as compared with unmutated DLBCL,
but only in the presence of wild-type
CARD11. In a phase I trial, BTK-inhi-
bitor ibrutinib generated a clinical (partial)
response in 40% of refractory nodal ABC-
DLBCL, both in patients with tumors
bearing CD79 mutations or a combina-
tion of CD79 and MYD88 mutations.
However, patients with only MYD88
mutations were refractory to this treat-
ment, reflecting B-cell receptor signaling
independency of MYD88-mutated tumors
(Wilson et al., 2012).
In summary, 7 out of 10 cases of
PCLBCL-LT showed genetic alterations
in the NF-kB pathway (Table 1). Although
precise representation is difficult in our
relatively small study cohort, for pathway-
activating mutations in CD79B, MYD88,
and CARD11 the percentages of tumors
affected strikingly resemble those present
in nodal ABC-DLBCL (Figure 1, Supple-
mentary Table S2 online). These findings
strongly suggest a role for constitutive
activation of the NF-kB pathway in
PCLBCL-LT, and provide a rationale to
develop therapy targeted at components
of the NF-kB pathway in this type of
lymphoma.
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